Voyager Therapeutics, Inc. Balance Sheet
VYGR|11 years of annual SEC 10-K data (FY2015-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 11 fiscal years. All figures from audited SEC 10-K filings.
Voyager Therapeutics, Inc. had $252M in total assets and $300M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.34 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $65.3M | $71.4M | $68.8M | $117.4M | $104.4M | $86.0M | $46.9M | $31.5M | $36.6M | $7.0M | $135.0K |
| Current Assets | $202.7M | $276.8M | $319.7M | $124.5M | $136.7M | $197.8M | $304.7M | $162.5M | $171.8M | $178.8M | $195.9M |
| PP&E (Net) | $13.1M | $14.3M | $16.5M | $17.9M | $21.9M | $25.4M | $18.0M | $12.8M | $10.3M | $7.9M | $3.2M |
| Total Assets | $252.3M | $393.1M | $351.3M | $159.4M | $193.9M | $261.6M | $354.8M | $177.0M | $184.5M | $189.6M | $229.5M |
| Current Liabilities | $26.5M | $49.8M | $64.5M | $72.6M | $51.0M | $26.8M | $76.0M | $31.7M | $15.9M | $13.8M | $23.9M |
| Shareholders' Equity | $299.8M | $59.0M | $95.1M | $154.3M | $99.5M | $46.4M | $134.1M | $135.9M | $169.1M | -$20.8M | -$3.8M |